[go: up one dir, main page]

KR950005327A - 임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자 - Google Patents

임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자 Download PDF

Info

Publication number
KR950005327A
KR950005327A KR1019940018956A KR19940018956A KR950005327A KR 950005327 A KR950005327 A KR 950005327A KR 1019940018956 A KR1019940018956 A KR 1019940018956A KR 19940018956 A KR19940018956 A KR 19940018956A KR 950005327 A KR950005327 A KR 950005327A
Authority
KR
South Korea
Prior art keywords
aicd2
bab
mab
bispecific antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019940018956A
Other languages
English (en)
Other versions
KR100347465B1 (ko
Inventor
스트리트마테르 볼프강
죄글레 카르로타-실비아
모우어 스테판
슈라벤 부르크하르트
빌트 마르틴
Original Assignee
위르겐 호이만, 라인하르트 슈틀러
메르크 파텐트 게젤샤프트 미트 베쉬랭크터 하프퉁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 위르겐 호이만, 라인하르트 슈틀러, 메르크 파텐트 게젤샤프트 미트 베쉬랭크터 하프퉁 filed Critical 위르겐 호이만, 라인하르트 슈틀러
Publication of KR950005327A publication Critical patent/KR950005327A/ko
Application granted granted Critical
Publication of KR100347465B1 publication Critical patent/KR100347465B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명읜 임파구 CD2 항원 및 기타 가변 종양 항원을 인식하는 매우 효과적인 신규의 이특이적 항체 단편에 관한 것이다. 더욱이 본 발명은 AICD2. M1 및 AICD2. M2로 명명된 2개의 신규 모노클론 항체에 관한 것이다. 이들중 최소한 하나가 이특이적 항체 단편인 이들항체의 결합은 종양 치료 및 진단 분야에 성공적으로 사용될 수 있다.

Description

임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. BAb<X, AICD2.M1>Y 또는 BAb<X, AICD2.M2>Y로 표시되는, 종양 세포의 에피토프에 대한 제1결합 부위 및 CD2 항원의 에피토프에 대한 제2결합 부위를 포함하는, 종양 세포의 용해에 유용한 이특이적 항체 분자 : 상기 표식에서, BAb는 이특이적 항체를 의미하고, X는 종양 항원을 인식하는 항체 결정기이고, AICD2.M1 및 AICD2.M2는 CD2 항원을 인식하는 항체이고, Y는 전체 항체의 일부이다.
  2. 제1항에 있어서, X가 모노클론 항체 MAb 425, MAb 361 또는 MAb 15로부터 유도되는 항체 결정기인 이특이적 항체 분자.
  3. 제1항 또는 제2항에 있어서, Y가 F(ab′)2 분자인 이특이적 항체 분자.
  4. 제1항 또는 제3항중 어느 한 항에 있어서, BAb<425, AICD2.M1>F(ab′)2, BAb<425, AICD2.M2>F(ab′)2, BAb<361, AICD2.M1>F(ab′)2, BAb<361, AICD2.M2>F(ab′)2, BAb<15, AICD2.M1>F(ab′)2, 및 BAb<15, AICD2.M2>F(ab′)2로 구성되는 군으로부터 선택되는 이특이적 항체 분자.
  5. 하나 또는 그 이상의 이황화 결합에 의해 연결된, 각각 2개의 동일한 L(경쇄-H(중쇄) 반(half) 분자를 포함하는 2개의 다른 모노클론 항체를 2개의 F(ab′)2 분자로 효소적 방법에 의해 전환시키고, 환원 조건하에서 각 F(ab′) 분자를 Fab′티올로 절단시키고, 이러한 각 항체의 Fab′분자중의 하나를 티올 활성화제로 유도체화하고, 종양 특이성을 가지는 활성화된 Fab′분자를 임파구 특이성을 가지는 비-활성화된 Fab′분자와 결합시키거나 또는 그 역으로 결합시켜 원하는 이특이적 항체 F(ab′)2 단편을 얻음으로써, 종양 세포의 에피토프에 대한 제1결합 부위 및 CD2항원의 에피토프에 대한 제2결합 부위를 포함하며, 모노클론 항체 AICD2.M1 및 AICD2.M2를 임파구 항원을 인식하는 항체로서 사용함을 특징으로 하는, 종양 세포의 용해에 유용한 이특이적 항체 F(ab′)단편의 제조방법.
  6. 제5항에 있어서, MAb 425, MAb 361 또는 MAb 15를 종양 세포를 인식하는 항체로 사용함을 특징으로 하는 방법.
  7. 세포주 1H 10(국제 기탁번호 DSM ACC2118)로부터 단리하여 얻어질 수 있는, 항원 CD2를 인식하는 모노클론 항체 AICD2.M1.
  8. 세포주 7D 3(국제 기탁번호 DSM ACC2119)로부터 단리하여 얻어질 수 있는, 항원 CD2를 인식하는 모노클론 항체 AICD2.M2.
  9. 하나 또는 그 이상의 약학적으로 허용가능한 담체, 부형제 또는 희석제와 함께, 제1항 내지 제4항 중 어느 한 항에 따른 하나 이상의 이특이적 항체 단편을 활성 성분으로서 포함하는 약학 제제.
  10. 이특이적 항체 단편 BAb<X, AICD2.M2>Y를 포함하는 제9항에 따른 제1약학 제제(I) 및 MAb AICD2.M1 또는 MAb<AICD2.M2>Y 또는 BAb<X, AICD2.M1>Y(여기서, X 및 Y는 제1항에서 정의한 바와 같다)를 포함하는 별도의 제2약학제제를 포함하는 약학적 킷트.
  11. 이특이적 항체 단편 BAb<X, AICD2.M1>Y를 포함하는 제9항에 따른 제1약학 제제 및 MAb AICD2.M2 또는 MAb<AICD2.M2>Y 또는 BAb<X, AICD2.M2>Y(여기서, X 및 Y는 제1항에서 정의한 바와 같다)를 포함하는 별도의 제2약학제제를 포함하는 약학적 킷트.
  12. 제11항에 있어서, 제제(I)이 이특이적 항체 단편 BAb<425, AICD2.M1>F(ab′)2 또는 BAb<361, AICD2.M1>F(ab′)2 또는 BAb<15, AICD2.M1>F(ab′)2를 포함하고, 제제(II)가 MAb<AICD2.M2>F(ab′)2를 포함하는 약학적 킷트.
  13. 부가적인 T-임파구의 임의적 존재하에 제10항 내지 제12항중 어느 한 항에 따른 약학적 킷트를 이용하여 종양 세포를 제제 (I)으로 처리한 후 제제(II)로 처리한 다음, 임의적으로 기존의 정제단계를 수행하는, 자가유래 골수 이식에서 생체의 종양 세포의 정화방법.
  14. 사람의 종양 치료 약물을 제조하기 위한, 제1항 내지 제4항중 어느 한 항에 따른 이특이적 항체 단편의 용도.
    ※참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019940018956A 1993-08-02 1994-08-01 임파구항원cd2및종양항원을인식하는이특이적트리거분자 Expired - Fee Related KR100347465B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93112330.1 1993-08-02
EP93112330 1993-08-02

Publications (2)

Publication Number Publication Date
KR950005327A true KR950005327A (ko) 1995-03-20
KR100347465B1 KR100347465B1 (ko) 2003-03-03

Family

ID=8213129

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940018956A Expired - Fee Related KR100347465B1 (ko) 1993-08-02 1994-08-01 임파구항원cd2및종양항원을인식하는이특이적트리거분자

Country Status (20)

Country Link
US (1) US5798229A (ko)
EP (1) EP0637593B1 (ko)
JP (2) JP3822653B2 (ko)
KR (1) KR100347465B1 (ko)
AT (1) ATE199378T1 (ko)
AU (1) AU683659B2 (ko)
CA (1) CA2129183C (ko)
CZ (1) CZ291071B6 (ko)
DE (1) DE69426743T2 (ko)
DK (1) DK0637593T3 (ko)
ES (1) ES2156587T3 (ko)
GR (1) GR3035926T3 (ko)
HU (1) HU218100B (ko)
NO (1) NO942850L (ko)
PL (1) PL176761B1 (ko)
PT (1) PT637593E (ko)
RU (1) RU2203319C2 (ko)
SK (1) SK283133B6 (ko)
UA (1) UA40577C2 (ko)
ZA (1) ZA945753B (ko)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE218143T1 (de) 1996-09-03 2002-06-15 Gsf Forschungszentrum Umwelt Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität
DK0826695T3 (da) * 1996-09-03 2002-04-15 Gsf Forschungszentrum Umwelt Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer
US6863887B1 (en) * 1998-03-30 2005-03-08 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
AU766675B2 (en) 1998-03-30 2003-10-23 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
AU767443B2 (en) * 1998-07-10 2003-11-13 Connex Gmbh Immunological reagent specifically interacting with the extracellular domain of the human zeta chain
WO2000018806A1 (de) * 1998-09-25 2000-04-06 Horst Lindhofer Bispezifische und trispezifische antikörper, die spezifisch mit induzierbaren oberflächenantigenen als operationelle zielstrukturen reagieren
MXPA02001877A (es) 1999-08-23 2002-08-20 Dana Farber Cancer Inst Inc Pd-1, un receptor para b7-4, y usos del mismo.
AU2002338272B2 (en) 2001-04-02 2007-10-11 Dana-Farber Cancer Institute, Inc. PD-1, a receptor for B7-4, and uses therefor
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
US20040265315A1 (en) * 2002-09-05 2004-12-30 Christine Dingivan Methods of preventing or treating T cell malignancies by administering CD2 antagonists
CN101812134A (zh) 2002-10-16 2010-08-25 欧洲凯尔特公司 结合细胞缔合的ca125/o772p的抗体及其使用方法
AU2004225941A1 (en) * 2003-03-28 2004-10-14 Elusys Therapeutics, Inc. Method and compositions for conversion of antibody activity
WO2005005479A1 (en) * 2003-05-09 2005-01-20 University Of Massachusetts Non-human animals expressing heterologous complement receptor type 1 (cr1) molecules on erythrocytes and uses therefor
JP2007510738A (ja) * 2003-11-06 2007-04-26 アイコス、コーポレーション ＣＤ１１ｄ（α−ｄ）インテグリンに特異的に結合する組成物を使用した慢性疼痛を処置する方法
AU2004297988A1 (en) * 2003-12-04 2005-06-23 Laboratoires Serono Sa Methods for identifying modulators of active KIT tyrosine kinase receptor
US20060263792A1 (en) * 2004-10-29 2006-11-23 Elusys Therapeutics, Inc. Use of CR1-binding molecules in clearance and induction of immune responses
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
WO2007114325A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
CA2700394C (en) 2007-09-26 2017-10-24 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) * 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
CA3221018A1 (en) 2008-01-15 2009-07-23 Ravindra Majeti Markers of acute myeloid leukemia stem cells
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
EP2414391B1 (en) 2009-04-02 2018-11-28 Roche Glycart AG Multispecific antibodies comprising full length antibodies and single chain fab fragments
MX2011010168A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos, trivalentes.
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
ES2927646T3 (es) 2009-09-15 2022-11-08 Univ Leland Stanford Junior Terapia anti-CD47 sinérgica para cánceres hematológicos
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
KR20120108967A (ko) 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
EP2499159B1 (en) 2009-11-13 2017-01-04 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
US8772459B2 (en) * 2009-12-02 2014-07-08 Imaginab, Inc. J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
EP2506881B1 (en) 2009-12-02 2024-03-06 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
ES2557454T3 (es) 2009-12-10 2016-01-26 F. Hoffmann-La Roche Ag Anticuerpos que se unen al dominio extracelular 4 de CSF1R humana y su utilización
ES2777901T3 (es) * 2009-12-25 2020-08-06 Chugai Pharmaceutical Co Ltd Método de modificación de polipéptidos para purificar multímeros polipeptídicos
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
KR101860963B1 (ko) * 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
MX340558B (es) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
KR20220082104A (ko) 2010-11-30 2022-06-16 추가이 세이야쿠 가부시키가이샤 세포상해 유도 치료제
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CN104093744A (zh) * 2011-10-11 2014-10-08 弗·哈夫曼-拉罗切有限公司 双特异性抗体的改进的组装
EP2791174B1 (en) * 2011-12-15 2018-02-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
KR20140127854A (ko) 2012-02-10 2014-11-04 제넨테크, 인크. 단일-쇄 항체 및 다른 이종다량체
BR112014028368A2 (pt) 2012-06-27 2017-11-14 Hoffmann La Roche método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
KR20150023889A (ko) 2012-06-27 2015-03-05 에프. 호프만-라 로슈 아게 2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
EP2879710B1 (en) 2012-08-03 2019-11-13 Dana-Farber Cancer Institute, Inc. Medical uses of agents that modulate immune cell activation and corresponding screening methods
EP2885002A4 (en) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES
CA2884313C (en) 2012-12-13 2023-01-03 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
CA2913490A1 (en) 2013-06-06 2014-12-11 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of cancer using pd-l1 isoforms
CA2919477A1 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
MX2016003593A (es) 2013-10-11 2016-06-02 Hoffmann La Roche Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CN106456748A (zh) 2014-01-08 2017-02-22 小利兰·斯坦福大学托管委员会 小细胞肺癌的靶向疗法
EP3094736A4 (en) 2014-01-14 2017-10-25 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
IL278350B (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
MA40069A (fr) 2014-05-29 2021-04-14 Macrogenics Inc Molécules de liaison trispécifiques et leurs procédés d'utilisation
CA2953567C (en) 2014-06-24 2023-09-05 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
ES3015000T3 (en) 2014-12-08 2025-04-28 Dana Farber Cancer Inst Inc Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
KR20230130148A (ko) 2015-03-04 2023-09-11 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
AU2016232749B2 (en) 2015-03-18 2021-09-23 The Johns Hopkins University Novel monoclonal antibody inhibitors targeting potassium channel KCNK9
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
AU2016281622C1 (en) 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
JP7065766B2 (ja) 2015-09-30 2022-05-12 アイジーエム バイオサイエンシズ インコーポレイテッド 改変ｊ鎖を有する結合分子
CN108463472A (zh) 2015-09-30 2018-08-28 Igm生物科学有限公司 具有修饰的j-链的结合分子
EP3362074B1 (en) 2015-10-16 2023-08-09 President and Fellows of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
CA3018332A1 (en) 2016-03-21 2017-09-28 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
WO2018112032A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
WO2018115051A1 (en) 2016-12-22 2018-06-28 F. Hoffmann-La Roche Ag Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
RU2663104C1 (ru) * 2017-07-13 2018-08-01 Общество с ограниченной ответственностью "Реал Таргет" Получение пегилированных фрагментов gd2-специфичных антител, индуцирующих прямую клеточную гибель gd2-позитивных опухолевых клеток, и их применение в терапии gd2-позитивных опухолей
EP3759125A4 (en) 2018-02-28 2021-12-08 Dana-Farber Cancer Institute, Inc. CANCER TREATMENT METHODS USING COMBINATIONS OF ANTI-BTNL2 BLOCKING AGENTS AND IMMUNE CHECKPOINTS
EP3962529A4 (en) 2019-04-30 2023-11-01 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
CR20210576A (es) 2019-05-21 2021-12-15 Novartis Ag Moléculas de unión a cd19 y usos de las mismas
WO2020236797A1 (en) * 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
EP4093513A4 (en) 2020-01-24 2024-05-08 Dana-Farber Cancer Institute, Inc. USE OF BIOMARKERS TO IMPROVE IMMUNOTHERAPY
WO2022239720A1 (ja) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 抗原への結合親和性を低減させた抗体
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
EP4440594A2 (en) 2021-11-29 2024-10-09 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
JP2025512377A (ja) 2022-04-11 2025-04-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ユニバーサルな腫瘍細胞殺傷のための組成物及び方法
WO2024059183A1 (en) 2022-09-14 2024-03-21 President And Fellows Of Harvard College Methods and compositions for modulation of piezo1 in the treatment of cancer
WO2025038750A2 (en) 2023-08-14 2025-02-20 President And Fellows Of Harvard College Methods and compositions for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US689469A (en) * 1901-05-03 1901-12-24 Joel Lewis Johnson Downen Farm-gate.
EP0260880A3 (en) * 1986-09-11 1990-03-07 Dana-Farber Cancer Institute, Inc. Turning on of cytotoxicity
EP0294703B1 (en) * 1987-06-10 1995-05-10 Dana-Farber Cancer Institute, Inc. Bifunctional antibody constructs and method for selectively destroying cell populations
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
AU658396B2 (en) * 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies

Also Published As

Publication number Publication date
AU6869894A (en) 1995-02-09
DE69426743D1 (de) 2001-04-05
RU94028282A (ru) 1996-07-20
JP2005336207A (ja) 2005-12-08
JP3822653B2 (ja) 2006-09-20
UA40577C2 (uk) 2001-08-15
NO942850L (no) 1995-02-03
SK91294A3 (en) 1996-11-06
ES2156587T3 (es) 2001-07-01
JP4231862B2 (ja) 2009-03-04
HU218100B (hu) 2000-06-28
KR100347465B1 (ko) 2003-03-03
PT637593E (pt) 2001-08-30
PL304510A1 (en) 1995-02-06
NO942850D0 (ko) 1994-08-01
ATE199378T1 (de) 2001-03-15
EP0637593B1 (en) 2001-02-28
DE69426743T2 (de) 2001-08-16
SK283133B6 (sk) 2003-03-04
HUT71309A (en) 1995-11-28
RU2203319C2 (ru) 2003-04-27
JPH0789873A (ja) 1995-04-04
CZ180294A3 (en) 1995-02-15
AU683659B2 (en) 1997-11-20
DK0637593T3 (da) 2001-06-25
CA2129183A1 (en) 1995-02-03
CZ291071B6 (cs) 2002-12-11
HU9402220D0 (en) 1994-10-28
EP0637593A1 (en) 1995-02-08
GR3035926T3 (en) 2001-08-31
PL176761B1 (pl) 1999-07-30
ZA945753B (en) 1995-03-15
CA2129183C (en) 2006-05-16
US5798229A (en) 1998-08-25

Similar Documents

Publication Publication Date Title
KR950005327A (ko) 임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
DE60331910D1 (de) Antikörper gegen humanes cd22 und deren therapeutische und diagnostische verwendungen
JP2002518460A5 (ko)
DE60333732D1 (de) Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
HUP0300806A2 (hu) A humán IL-1béta-nak megfelelő antitestek
NI200600098A (es) Anticuerpos que se unen al receptor de interleuquina-4
BRPI9809391B8 (pt) processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
ATE382053T1 (de) System zur antikörperexpression und- synthese
EP1705191A3 (en) Anti-interleukin-18 antibody
TW200500377A (en) Method of humanizing immune system molecules
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
NO913428L (no) Humant intra-acrosomalt sperma-antigen for anvendelse i en befruktningshindrende vaksine.
BR0207151A (pt) Moléculas de aglutinação terapêuticas
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
KR900013986A (ko) 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
AR045765A1 (es) Moleculas de union a cd45 y uso terapeutico
BR0210648A (pt) Variante de uma molécula imunointerativa, anticorpo monoclonal, forma disimunizada de anticorpo monoclonal 3b6, método para a geração de um anticorpo monoclonal desimunizado, molécula de anticorpo desimunizada, anticorpo desimunizado, anticorpo monoclonal de murino variante 3b6 desimunizado, variante de um anticorpo monoclonal de murino 3b6 desimunizado para uso em humanos, método para a detecção de um coágulo sanguìneo em um paciente humano, método para a detecção de um coágulo sanguìneo ou de um seu fragmento de ligação a antìgeno, método para a facilitação da dissolução ou da remoção de um coágulo sanguìneo em um humano, uso de um anticorpo monoclonal derivado de murino variante, e, conjugado
ATE353337T1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
NO316916B1 (no) Anvendelse av en bispesifikk antistoffkonstruksjon som er rettet mot CCR5 og CD3 for fremstilling av en farmasoytisk sammensetning for behandling av kronisk artritt, autoimmunesykdommer, allergiske reaksjoner eller for reduksjon av kjemokinreseptoruttrykk
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye
RU94045907A (ru) Вич-антитела человека или их фрагменты, экспрессионные кассеты, клетки-хозяева, фармацевтические композиции, способ защиты
IT1284076B1 (it) Frammenti f(ab&#39;)2 e relative immunoglobuline igg, attivi come anticorpi specifici verso farmaci e i loro metaboliti, e loro

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20080701

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090724

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090724

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000